Details of the Drug

General Information of Drug (ID: DMTW6IU)

Drug Name

Methadone

Synonyms

Adanon; Algovetin; Althose; Amidon; Amidone; Biscuits; Dextromethadone; Diaminon; Dollies; Dolly; Dolophin; Dolophine; Heptadone; Heptanon; Ketalgin; Levometadona; Levomethadonum; Levothyl; Metadona; Metadone; Metasedin; Methadon; Methadona; Methadonum; Methaquaione; Phenadone; Polamidone; Polamivet; Westadone; Dolophine HCL; Levomethadone [INN]; Metadona [Spanish]; Metadone [DCIT]; Methadona [Spanish]; Methadone HCL Intensol; Methadone M; Methadonum [Latin]; Racemic methadone; A 4624; AN 148; Hoechst 10820; K 174; Amidone (TN); D-Methadone; Dl-Methadone; Dolophine (TN); Heptadon (TN); Heptanon (pharmaceutical); L-Methadone; L-Polamidon; L-Polamivet; Levometadona [INN-Spanish]; Levomethadonum [INN-Latin]; Metadona [INN-Spanish]; Methadone (BAN); Methadone [INN:BAN]; Methadonum [INN-Latin]; Methadose (TN); Physeptone (TN); Sedo-Rapide; Symoron (TN); Dolophine (*Hydrochloride*); Fenadone (*Hydrochloride*); Heptadone (*Hydrochloride*); Heptanon (*Hydrochloride*); Hoescht 10820 (*Hydrochloride*); Phenadone (*Hydrochloride*); AN-148 (*Hydrochloride*); L-(+)-Methadone; S-(+)-Methadone; D-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (+)-Methadone; (+-)-Methadone; (+/-)-Methadone; (+/-)-Tussal; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)-(9CI); 6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture; 6-(dimethylamino)-4,4-diphenylheptan-3-one; 6-Dimethylamino-4,4-diphenyl-3-heptanone; 6-dimethylamino-4,4-di(phenyl)heptan-3-one; 6S-Methadone

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Dry cough	MD12	Approved	[2]
Pain	MG30-MG3Z	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

309.4

Logarithm of the Partition Coefficient (xlogp)

3.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-7.5 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 36-100% [3]
Clearance: The clearance of drug is 5.9C13 L/h [5]
Elimination: 24% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 15C207 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.61574 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.21% [7]
Vd: The volume of distribution (Vd) of drug is 189-470 L [5]
Water Solubility: The ability of drug to dissolve in water is measured as 120 mg/mL [4]

Chemical Identifiers

Formula: C21H27NO
IUPAC Name: 6-(dimethylamino)-4,4-diphenylheptan-3-one
Canonical SMILES: CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
InChI: InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
InChIKey: USSIQXCVUWKGNF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4095
ChEBI ID: CHEBI:6807
CAS Number: 76-99-3
DrugBank ID: DB00333
TTD ID: D09OJQ
VARIDT ID: DR00141
INTEDE ID: DR1039
ACDINA ID: D00406

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor (OPR)	TTN4QDT	NOUNIPROTAC	Agonist	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[10]
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[10]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[11]
Aromatase (CYP19A1)	DEQX145	CP19A_HUMAN	Substrate	[12]
Cytochrome P450 2B6 (CYP2B6)_{Main DME}	DEPKLMQ	CP2B6_HUMAN	Substrate	[10]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[10]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[10]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-1-acid glycoprotein 2 (ORM2)	OTRJGZP8	A1AG2_HUMAN	Protein Interaction/Cellular Processes	[14]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Protein Interaction/Cellular Processes	[15]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[16]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Protein Interaction/Cellular Processes	[15]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Gene/Protein Processing	[17]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Protein Interaction/Cellular Processes	[18]
Interleukin-2 (IL2)	OTGI4NSA	IL2_HUMAN	Gene/Protein Processing	[19]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Gene/Protein Processing	[19]
Leptin (LEP)	OT5Q7ODW	LEP_HUMAN	Gene/Protein Processing	[20]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Post-Translational Modifications	[19]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Methadone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Dextromethorphan	DMUDJZM	Moderate	Additive CNS depression effects by the combination of Methadone and Dextromethorphan.	Cough [MD12]	[21]
-----------

Coadministration of a Drug Treating the Disease Different from Methadone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Methadone and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[22]
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Methadone caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[23]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Methadone and Ivosidenib.	Acute myeloid leukaemia [2A60]	[24]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Methadone and Midostaurin.	Acute myeloid leukaemia [2A60]	[25]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Methadone and Idarubicin.	Acute myeloid leukaemia [2A60]	[25]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Methadone and Daunorubicin.	Acute myeloid leukaemia [2A60]	[25]
Arn-509	DMT81LZ	Major	Increased metabolism of Methadone caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[23]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Methadone and Gilteritinib.	Acute myeloid leukaemia [2A60]	[25]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Methadone and Oliceridine.	Acute pain [MG31]	[26]
Chlorzoxazone	DMCYVDT	Major	Additive CNS depression effects by the combination of Methadone and Chlorzoxazone.	Acute pain [MG31]	[27]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Methadone due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[28]
Scopolamine	DMOM8AL	Moderate	Additive CNS depression effects by the combination of Methadone and Scopolamine.	Addictive disorder [6C50-6C5Z]	[29]
Mitotane	DMU1GX0	Major	Increased metabolism of Methadone caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[23]
Terfenadine	DM4KLPT	Major	Increased risk of prolong QT interval by the combination of Methadone and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[25]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Methadone and Tacrine.	Alzheimer disease [8A20]	[25]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Methadone and Galantamine.	Alzheimer disease [8A20]	[25]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Methadone and Rivastigmine.	Alzheimer disease [8A20]	[25]
Donepezil	DMIYG7Z	Minor	Decreased metabolism of Methadone caused by Donepezil mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[30]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Methadone and Metronidazole.	Amoebiasis [1A36]	[31]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Methadone due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[28]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Methadone and Ivabradine.	Angina pectoris [BA40]	[28]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Methadone and Bepridil.	Angina pectoris [BA40]	[25]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Methadone and Dronedarone.	Angina pectoris [BA40]	[25]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Methadone caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[32]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Methadone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[33]
Buspirone	DMBS632	Major	Additive CNS depression effects by the combination of Methadone and Buspirone.	Anxiety disorder [6B00-6B0Z]	[27]
Clorazepate	DMC3JST	Major	Additive CNS depression effects by the combination of Methadone and Clorazepate.	Anxiety disorder [6B00-6B0Z]	[34]
Alprazolam	DMC7XDN	Major	Additive CNS depression effects by the combination of Methadone and Alprazolam.	Anxiety disorder [6B00-6B0Z]	[27]
Methylphenobarbital	DMDSWAG	Major	Additive CNS depression effects by the combination of Methadone and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[35]
Hydroxyzine	DMF8Y74	Major	Additive CNS depression effects by the combination of Methadone and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[27]
Halazepam	DMPFWO6	Major	Additive CNS depression effects by the combination of Methadone and Halazepam.	Anxiety disorder [6B00-6B0Z]	[27]
Chlordiazepoxide	DMTN5XI	Major	Additive CNS depression effects by the combination of Methadone and Chlordiazepoxide.	Anxiety disorder [6B00-6B0Z]	[27]
Chlormezanone	DMTWUXR	Major	Additive CNS depression effects by the combination of Methadone and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[27]
Clobazam - Lundbeck	DMW1OQ0	Major	Additive CNS depression effects by the combination of Methadone and Clobazam - Lundbeck.	Anxiety disorder [6B00-6B0Z]	[27]
Oxazepam	DMXNZM4	Major	Additive CNS depression effects by the combination of Methadone and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[27]
Promazine	DMZAL7W	Major	Increased risk of prolong QT interval by the combination of Methadone and Promazine.	Appearance/behaviour symptom [MB23]	[25]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Methadone and Cilostazol.	Arterial occlusive disease [BD40]	[25]
Voriconazole	DMAOL2S	Major	Increased risk of prolong QT interval by the combination of Methadone and Voriconazole.	Aspergillosis [1F20]	[25]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Methadone and Posaconazole.	Aspergillosis [1F20]	[25]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Methadone and Levalbuterol.	Asthma [CA23]	[36]
Terbutaline	DMD4381	Major	Increased risk of prolong QT interval by the combination of Methadone and Terbutaline.	Asthma [CA23]	[37]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Methadone and Pirbuterol.	Asthma [CA23]	[37]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Methadone and Salbutamol.	Asthma [CA23]	[38]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Methadone and Formoterol.	Asthma [CA23]	[37]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Methadone and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[25]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Methadone and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[25]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Methadone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Oritavancin	DM28D05	Moderate	Increased metabolism of Methadone caused by Oritavancin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Ciprofloxacin XR	DM2NLS9	Major	Decreased metabolism of Methadone caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[39]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Methadone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[39]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Methadone and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[25]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Methadone and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[25]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Methadone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Chloramphenicol	DMFXEWT	Moderate	Decreased metabolism of Methadone caused by Chloramphenicol mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[32]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Methadone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Methadone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Methadone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Methadone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[32]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Methadone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Methadone and Retigabine.	Behcet disease [4A62]	[25]
Cariprazine	DMJYDVK	Major	Additive CNS depression effects by the combination of Methadone and Cariprazine.	Bipolar disorder [6A60]	[27]
Pexidartinib	DMS2J0Z	Major	Increased metabolism of Methadone caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[23]
Loperamide	DMOJZQ9	Moderate	Additive CNS depression effects by the combination of Methadone and Loperamide.	Bowel habit change [ME05]	[28]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Methadone and Eribulin.	Breast cancer [2C60-2C6Y]	[25]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Methadone and Lapatinib.	Breast cancer [2C60-2C6Y]	[25]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Methadone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Methadone caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[41]
Tamoxifen	DMLB0EZ	Major	Increased risk of prolong QT interval by the combination of Methadone and Tamoxifen.	Breast cancer [2C60-2C6Y]	[25]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Methadone and Toremifene.	Breast cancer [2C60-2C6Y]	[25]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Methadone and Bosutinib.	Breast cancer [2C60-2C6Y]	[25]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Methadone and Grepafloxacin.	Bronchitis [CA20]	[40]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Methadone and Sotalol.	Cardiac arrhythmia [BC9Z]	[25]
Secobarbital	DM14RF5	Major	Additive CNS depression effects by the combination of Methadone and Secobarbital.	Chronic insomnia [7A00]	[32]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Methadone and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[25]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Methadone and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Methadone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[36]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Methadone and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Methadone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Methadone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Methadone caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[23]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Methadone and Dihydrocodeine.	Chronic pain [MG30]	[34]
Levomilnacipran	DMV26S8	Moderate	Additive serotonergic effects by the combination of Methadone and Levomilnacipran.	Chronic pain [MG30]	[21]
Oxaliplatin	DMQNWRD	Major	Increased risk of prolong QT interval by the combination of Methadone and Oxaliplatin.	Colorectal cancer [2B91]	[25]
Isoproterenol	DMK7MEY	Major	Increased risk of ventricular arrhythmias by the combination of Methadone and Isoproterenol.	Conduction disorder [BC63]	[37]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Methadone and Olopatadine.	Conjunctiva disorder [9A60]	[42]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Methadone and Halothane.	Corneal disease [9A76-9A78]	[25]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Methadone and Propofol.	Corneal disease [9A76-9A78]	[43]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Methadone and Sevoflurane.	Corneal disease [9A76-9A78]	[25]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Methadone and Probucol.	Coronary atherosclerosis [BA80]	[25]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Methadone and Clofazimine.	Crohn disease [DD70]	[25]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Methadone and Mifepristone.	Cushing syndrome [5A70]	[25]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Methadone and Pasireotide.	Cushing syndrome [5A70]	[25]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Methadone and Osilodrostat.	Cushing syndrome [5A70]	[25]
Aminoglutethimide	DMWFHMZ	Major	Increased metabolism of Methadone caused by Aminoglutethimide mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[23]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Methadone caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[44]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Methadone and Ethanol.	Cystitis [GC00]	[45]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Methadone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[32]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Methadone caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Methadone and Sertraline.	Depression [6A70-6A7Z]	[25]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Methadone and Trimipramine.	Depression [6A70-6A7Z]	[25]
Cyclobenzaprine	DM1YBRM	Major	Additive CNS depression effects by the combination of Methadone and Cyclobenzaprine.	Depression [6A70-6A7Z]	[27]
Imipramine	DM2NUH3	Major	Increased risk of prolong QT interval by the combination of Methadone and Imipramine.	Depression [6A70-6A7Z]	[25]
Fluoxetine	DM3PD2C	Major	Decreased metabolism of Methadone caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[46]
Nortriptyline	DM4KDYJ	Major	Increased risk of prolong QT interval by the combination of Methadone and Nortriptyline.	Depression [6A70-6A7Z]	[25]
Vilazodone	DM4LECQ	Moderate	Additive serotonergic effects by the combination of Methadone and Vilazodone.	Depression [6A70-6A7Z]	[21]
Paroxetine	DM5PVQE	Moderate	Additive serotonergic effects by the combination of Methadone and Paroxetine.	Depression [6A70-6A7Z]	[21]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Methadone and Selegiline.	Depression [6A70-6A7Z]	[22]
Vortioxetine	DM6F1PU	Moderate	Additive serotonergic effects by the combination of Methadone and Vortioxetine.	Depression [6A70-6A7Z]	[21]
Duloxetine	DM9BI7M	Moderate	Increased plasma concentrations of Methadone and Duloxetine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[47]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Methadone and Isocarboxazid.	Depression [6A70-6A7Z]	[22]
Milnacipran	DMBFE74	Moderate	Additive serotonergic effects by the combination of Methadone and Milnacipran.	Depression [6A70-6A7Z]	[21]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Methadone and Escitalopram.	Depression [6A70-6A7Z]	[25]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Methadone and Tranylcypromine.	Depression [6A70-6A7Z]	[22]
Desvenlafaxine	DMHD4PE	Moderate	Additive CNS depression effects by the combination of Methadone and Desvenlafaxine.	Depression [6A70-6A7Z]	[21]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Methadone and OPC-34712.	Depression [6A70-6A7Z]	[27]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Methadone and Phenelzine.	Depression [6A70-6A7Z]	[22]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Methadone and Clomipramine.	Depression [6A70-6A7Z]	[25]
Trazodone	DMK1GBJ	Major	Increased risk of prolong QT interval by the combination of Methadone and Trazodone.	Depression [6A70-6A7Z]	[25]
Amoxapine	DMKITQE	Major	Increased risk of prolong QT interval by the combination of Methadone and Amoxapine.	Depression [6A70-6A7Z]	[25]
Mirtazapine	DML53ZJ	Major	Increased risk of prolong QT interval by the combination of Methadone and Mirtazapine.	Depression [6A70-6A7Z]	[25]
Protriptyline	DMNHTZI	Major	Increased risk of prolong QT interval by the combination of Methadone and Protriptyline.	Depression [6A70-6A7Z]	[25]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Methadone and Doxepin.	Depression [6A70-6A7Z]	[48]
Maprotiline	DMPWB7T	Major	Increased risk of prolong QT interval by the combination of Methadone and Maprotiline.	Depression [6A70-6A7Z]	[25]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Methadone and Esketamine.	Depression [6A70-6A7Z]	[31]
Griseofulvin	DMK54YG	Moderate	Increased metabolism of Methadone caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[23]
Hyoscyamine	DM804UR	Moderate	Additive CNS depression effects by the combination of Methadone and Hyoscyamine.	Digestive system disease [DE2Z]	[29]
Mepenzolate	DM8YU2F	Moderate	Additive CNS depression effects by the combination of Methadone and Mepenzolate.	Digestive system disease [DE2Z]	[29]
5-hydroxy-L-tryptophan	DMDWZGJ	Moderate	Additive serotonergic effects by the combination of Methadone and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[21]
Oxybutynine	DMJPBAX	Moderate	Additive CNS depression effects by the combination of Methadone and Oxybutynine.	Discovery agent [N.A.]	[29]
Heroin diacetylmorphine	DMDBWHY	Major	Additive CNS depression effects by the combination of Methadone and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[34]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Methadone and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[25]
Trihexyphenidyl	DMB19L8	Moderate	Additive CNS depression effects by the combination of Methadone and Trihexyphenidyl.	Dystonic disorder [8A02]	[49]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Methadone and Deutetrabenazine.	Dystonic disorder [8A02]	[25]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Methadone and Ingrezza.	Dystonic disorder [8A02]	[25]
Fenfluramine	DM0762O	Moderate	Additive serotonergic effects by the combination of Methadone and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[21]
Diazepam	DM08E9O	Major	Additive CNS depression effects by the combination of Methadone and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[27]
Primidone	DM0WX6I	Major	Increased metabolism of Methadone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Methadone caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Oxcarbazepine	DM5PU6O	Major	Increased metabolism of Methadone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Gabapentin	DM6T924	Major	Additive CNS depression effects by the combination of Methadone and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[50]
Cenobamate	DM8KLU9	Major	Increased metabolism of Methadone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Methadone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Methadone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Clonazepam	DMTO13J	Major	Additive CNS depression effects by the combination of Methadone and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[27]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Methadone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Methadone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Carbamazepine	DMZOLBI	Major	Increased metabolism of Methadone caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Eslicarbazepine	DMZREFQ	Major	Increased metabolism of Methadone caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Timolol	DM3NXRU	Moderate	Decreased metabolism of Methadone caused by Timolol mediated inhibition of CYP450 enzyme.	Essential hypertension [BA00]	[51]
Dantrolene	DM1D8XY	Major	Additive CNS depression effects by the combination of Methadone and Dantrolene.	Fever [MG26]	[27]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Methadone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[23]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Methadone and Solifenacin.	Functional bladder disorder [GC50]	[25]
Tolterodine	DMSHPW8	Moderate	Additive CNS depression effects by the combination of Methadone and Tolterodine.	Functional bladder disorder [GC50]	[29]
Darifenacin	DMWXLYZ	Moderate	Additive antimotility effects by the combination of Methadone and Darifenacin.	Functional bladder disorder [GC50]	[52]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Methadone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[31]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Methadone and Pentamidine.	Fungal infection [1F29-1F2F]	[25]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Methadone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[53]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Methadone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[54]
Propantheline	DM2EN6G	Moderate	Additive CNS depression effects by the combination of Methadone and Propantheline.	Gastric ulcer [DA60]	[29]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Methadone caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[32]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Methadone and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[25]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Methadone and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[25]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Methadone and Brimonidine.	Glaucoma [9C61]	[55]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Methadone caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[23]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Methadone caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[32]
Rifampin	DMA8J1G	Major	Increased metabolism of Methadone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[44]
Rifapentine	DMCHV4I	Major	Increased metabolism of Methadone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[23]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Methadone and Procarbazine.	Hodgkin lymphoma [2B30]	[22]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Methadone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Methadone and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Methadone caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Methadone and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Methadone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Methadone and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[48]
Rilpivirine	DMJ0QOW	Major	Increased metabolism of Methadone caused by Rilpivirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Methadone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Methadone caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[32]
Diltiazem	DMAI7ZV	Moderate	Decreased metabolism of Methadone caused by Diltiazem mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[32]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Methadone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[32]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Methadone caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[23]
Belladonna	DM2RBWK	Moderate	Additive antimotility effects by the combination of Methadone and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[52]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Methadone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[32]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Methadone and Suvorexant.	Insomnia [7A00-7A0Z]	[27]
Amobarbital	DM0GQ8N	Major	Increased metabolism of Methadone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[32]
Ramelteon	DM7IW9J	Major	Additive CNS depression effects by the combination of Methadone and Ramelteon.	Insomnia [7A00-7A0Z]	[27]
Eszopiclone	DM8RZ9H	Major	Additive CNS depression effects by the combination of Methadone and Eszopiclone.	Insomnia [7A00-7A0Z]	[27]
Flurazepam	DMAL4G0	Major	Additive CNS depression effects by the combination of Methadone and Flurazepam.	Insomnia [7A00-7A0Z]	[27]
Triazolam	DMETYK5	Major	Additive CNS depression effects by the combination of Methadone and Triazolam.	Insomnia [7A00-7A0Z]	[27]
Zaleplon	DMGFWSM	Major	Additive CNS depression effects by the combination of Methadone and Zaleplon.	Insomnia [7A00-7A0Z]	[27]
Propiomazine	DMKY8V1	Major	Additive CNS depression effects by the combination of Methadone and Propiomazine.	Insomnia [7A00-7A0Z]	[27]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Methadone and Tasimelteon.	Insomnia [7A00-7A0Z]	[27]
Paraldehyde	DMOC1BX	Major	Additive CNS depression effects by the combination of Methadone and Paraldehyde.	Insomnia [7A00-7A0Z]	[27]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Methadone and ITI-007.	Insomnia [7A00-7A0Z]	[27]
Zolpidem	DMWOSKJ	Major	Additive CNS depression effects by the combination of Methadone and Zolpidem.	Insomnia [7A00-7A0Z]	[27]
Quazepam	DMY4D87	Major	Additive CNS depression effects by the combination of Methadone and Quazepam.	Insomnia [7A00-7A0Z]	[27]
Estazolam	DMZGXUM	Major	Additive CNS depression effects by the combination of Methadone and Estazolam.	Insomnia [7A00-7A0Z]	[27]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Methadone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[58]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Methadone and Phenolphthalein.	Irritable bowel syndrome [DD91]	[25]
Clidinium	DMUMQZ0	Moderate	Additive antimotility effects by the combination of Methadone and Clidinium.	Irritable bowel syndrome [DD91]	[52]
Dicyclomine	DMZSDGX	Moderate	Additive antimotility effects by the combination of Methadone and Dicyclomine.	Irritable bowel syndrome [DD91]	[52]
Remimazolam	DMLVSYX	Major	Additive CNS depression effects by the combination of Methadone and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[27]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Methadone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[28]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Methadone and Crizotinib.	Lung cancer [2C25]	[59]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Methadone caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[23]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Methadone and Ceritinib.	Lung cancer [2C25]	[25]
PF-06463922	DMKM7EW	Major	Increased metabolism of Methadone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[23]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Methadone and Osimertinib.	Lung cancer [2C25]	[25]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Methadone and Selpercatinib.	Lung cancer [2C25]	[28]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Methadone and Lumefantrine.	Malaria [1F40-1F45]	[31]
Meprobamate	DMHM93Y	Major	Additive CNS depression effects by the combination of Methadone and Meprobamate.	Malaria [1F40-1F45]	[27]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Methadone and Halofantrine.	Malaria [1F40-1F45]	[60]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Methadone and Chloroquine.	Malaria [1F40-1F45]	[61]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Methadone and Hydroxychloroquine.	Malaria [1F40-1F45]	[61]
Quinine	DMSWYF5	Major	Increased risk of prolong QT interval by the combination of Methadone and Quinine.	Malaria [1F40-1F45]	[25]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Methadone and Primaquine.	Malaria [1F40-1F45]	[25]
Mefloquine	DMWT905	Major	Increased risk of prolong QT interval by the combination of Methadone and Mefloquine.	Malaria [1F40-1F45]	[25]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Methadone and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[25]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Methadone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[32]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Methadone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[32]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Methadone and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[62]
Blinatumomab	DMGECIJ	Moderate	Decreased metabolism of Methadone caused by Blinatumomab mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[63]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Methadone due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[31]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Methadone and Vemurafenib.	Melanoma [2C30]	[25]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Methadone and LGX818.	Melanoma [2C30]	[25]
Dabrafenib	DMX6OE3	Major	Increased metabolism of Methadone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[23]
Danazol	DML8KTN	Moderate	Decreased metabolism of Methadone caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[32]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Methadone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[64]
Nitisinone	DMVS9WQ	Moderate	Decreased metabolism of Methadone caused by Nitisinone mediated inhibition of CYP450 enzyme.	Metabolism inborn error [5C50]	[25]
Almogran	DM7I64Z	Moderate	Additive CNS depression effects by the combination of Methadone and Almogran.	Migraine [8A80]	[21]
Frovatriptan	DM7RE8P	Moderate	Additive serotonergic effects by the combination of Methadone and Frovatriptan.	Migraine [8A80]	[21]
Rizatriptan	DMDJMA3	Moderate	Additive serotonergic effects by the combination of Methadone and Rizatriptan.	Migraine [8A80]	[21]
Naratriptan	DMO50U2	Moderate	Additive serotonergic effects by the combination of Methadone and Naratriptan.	Migraine [8A80]	[21]
Sumatriptan	DMVYXR8	Moderate	Additive serotonergic effects by the combination of Methadone and Sumatriptan.	Migraine [8A80]	[21]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Methadone and Lasmiditan.	Migraine [8A80]	[65]
Exjade	DMHPRWG	Moderate	Increased metabolism of Methadone caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[23]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Methadone and Flibanserin.	Mood disorder [6A60-6E23]	[66]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Methadone and Panobinostat.	Multiple myeloma [2A83]	[67]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Methadone and Thalidomide.	Multiple myeloma [2A83]	[68]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Methadone and Siponimod.	Multiple sclerosis [8A40]	[31]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Methadone and Fingolimod.	Multiple sclerosis [8A40]	[25]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Methadone and Ozanimod.	Multiple sclerosis [8A40]	[69]
Carisoprodol	DMWR1JC	Major	Additive CNS depression effects by the combination of Methadone and Carisoprodol.	Musculoskeletal disorder [FA00-FC0Z]	[27]
Rifabutin	DM1YBHK	Minor	Increased metabolism of Methadone caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[70]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Methadone and Romidepsin.	Mycosis fungoides [2B01]	[25]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Methadone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[32]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Methadone caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[32]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Methadone and Dasatinib.	Myeloproliferative neoplasm [2A20]	[25]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Methadone due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[71]
Modafinil	DMYILBE	Major	Increased metabolism of Methadone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[23]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Methadone and Droperidol.	Nausea/vomiting [MD90]	[25]
Prochlorperazine	DM53SRA	Major	Increased risk of prolong QT interval by the combination of Methadone and Prochlorperazine.	Nausea/vomiting [MD90]	[25]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Methadone and Promethazine.	Nausea/vomiting [MD90]	[25]
Palonosetron	DMBHMOX	Major	Increased risk of prolong QT interval by the combination of Methadone and Palonosetron.	Nausea/vomiting [MD90]	[25]
Metoclopramide	DMFA5MY	Moderate	Additive antimotility effects by the combination of Methadone and Metoclopramide.	Nausea/vomiting [MD90]	[72]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Methadone and Granisetron.	Nausea/vomiting [MD90]	[25]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Methadone and Dolasetron.	Nausea/vomiting [MD90]	[25]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Methadone and Ondansetron.	Nausea/vomiting [MD90]	[25]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Methadone and Bupropion.	Nicotine use disorder [6C4A]	[73]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Methadone and Entrectinib.	Non-small cell lung cancer [2C25]	[25]
Sibutramine	DMFJTDI	Moderate	Additive serotonergic effects by the combination of Methadone and Sibutramine.	Obesity [5B80-5B81]	[21]
Dexfenfluramine	DMJ7YDS	Moderate	Additive CNS depression effects by the combination of Methadone and Dexfenfluramine.	Obesity [5B80-5B81]	[21]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Methadone and Levomethadyl Acetate.	Opioid use disorder [6C43]	[28]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Methadone and Lofexidine.	Opioid use disorder [6C43]	[25]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Methadone and Apraclonidine.	Optic nerve disorder [9C40]	[55]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Methadone caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[31]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Methadone and Rucaparib.	Ovarian cancer [2C73]	[25]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Methadone and Pentazocine.	Pain [MG30-MG3Z]	[74]
Dextropropoxyphene	DM23HCX	Major	Decreased metabolism of Methadone caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[75]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Methadone and Butorphanol.	Pain [MG30-MG3Z]	[74]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Methadone and Oxymorphone.	Pain [MG30-MG3Z]	[27]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Methadone and Levorphanol.	Pain [MG30-MG3Z]	[27]
Dezocine	DMJDB0Y	Major	Additive hypotensive effects by the combination of Methadone and Dezocine.	Pain [MG30-MG3Z]	[74]
Flavoxate	DMKV4NL	Moderate	Additive CNS depression effects by the combination of Methadone and Flavoxate.	Pain [MG30-MG3Z]	[29]
Nalbuphine	DMOSQGU	Major	Additive hypotensive effects by the combination of Methadone and Nalbuphine.	Pain [MG30-MG3Z]	[74]
Buprenorphine	DMPRI8G	Major	Increased risk of prolong QT interval by the combination of Methadone and Buprenorphine.	Pain [MG30-MG3Z]	[25]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Methadone and Hydrocodone.	Pain [MG30-MG3Z]	[27]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Methadone and Meperidine.	Pain [MG30-MG3Z]	[27]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Methadone and Oxycodone.	Pain [MG30-MG3Z]	[27]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Methadone and Triclabendazole.	Parasitic worm infestation [1F90]	[25]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Methadone and Safinamide.	Parkinsonism [8A00]	[22]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Methadone and Rasagiline.	Parkinsonism [8A00]	[22]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Methadone and Biperiden.	Parkinsonism [8A00]	[49]
Procyclidine	DMHFJDT	Moderate	Additive CNS depression effects by the combination of Methadone and Procyclidine.	Parkinsonism [8A00]	[49]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Methadone and Pimavanserin.	Parkinsonism [8A00]	[25]
Orphenadrine	DMW542E	Major	Additive CNS depression effects by the combination of Methadone and Orphenadrine.	Parkinsonism [8A00]	[27]
Apomorphine	DMX38HQ	Major	Increased risk of prolong QT interval by the combination of Methadone and Apomorphine.	Parkinsonism [8A00]	[25]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Methadone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[76]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Methadone and Lindane.	Pediculosis [1G00]	[77]
Methylscopolamine	DM5VWOB	Moderate	Additive CNS depression effects by the combination of Methadone and Methylscopolamine.	Peptic ulcer [DA61]	[29]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Methadone and Famotidine.	Peptic ulcer [DA61]	[31]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Methadone and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[78]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Methadone and Lefamulin.	Pneumonia [CA40]	[79]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Methadone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[32]
Ritodrine	DM4V6RL	Major	Increased risk of ventricular arrhythmias by the combination of Methadone and Ritodrine.	Preterm labour/delivery [JB00]	[37]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Methadone and Degarelix.	Prostate cancer [2C82]	[25]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Methadone and ABIRATERONE.	Prostate cancer [2C82]	[25]
Nilutamide	DMFN07X	Major	Increased risk of prolong QT interval by the combination of Methadone and Nilutamide.	Prostate cancer [2C82]	[25]
Enzalutamide	DMGL19D	Major	Increased metabolism of Methadone caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[23]
Flutamide	DMK0O7U	Major	Increased risk of prolong QT interval by the combination of Methadone and Flutamide.	Prostate cancer [2C82]	[25]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Methadone and Relugolix.	Prostate cancer [2C82]	[25]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Methadone and Bicalutamide.	Prostate cancer [2C82]	[25]
Alfuzosin	DMZVMKF	Major	Increased risk of prolong QT interval by the combination of Methadone and Alfuzosin.	Prostate hyperplasia [GA90]	[25]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Methadone due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[28]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Methadone due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[28]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Methadone and Levomepromazine.	Psychotic disorder [6A20-6A25]	[25]
Triflupromazine	DMKFQJP	Major	Increased risk of prolong QT interval by the combination of Methadone and Triflupromazine.	Psychotic disorder [6A20-6A25]	[25]
Bosentan	DMIOGBU	Major	Increased metabolism of Methadone caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[23]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Methadone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[80]
Sorafenib	DMS8IFC	Major	Increased risk of prolong QT interval by the combination of Methadone and Sorafenib.	Renal cell carcinoma [2C90]	[25]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Methadone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[25]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Methadone due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Methadone due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Methadone due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Methadone due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Dexamethasone	DMMWZET	Major	Increased metabolism of Methadone caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[23]
Nafcillin	DMN9RPO	Major	Increased metabolism of Methadone caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[23]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Methadone due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Methadone and Quetiapine.	Schizophrenia [6A20]	[25]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Methadone and Mesoridazine.	Schizophrenia [6A20]	[25]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Methadone and Thioridazine.	Schizophrenia [6A20]	[25]
Aripiprazole	DM3NUMH	Major	Additive CNS depression effects by the combination of Methadone and Aripiprazole.	Schizophrenia [6A20]	[27]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Methadone and Iloperidone.	Schizophrenia [6A20]	[25]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Methadone and Paliperidone.	Schizophrenia [6A20]	[25]
Loxapine	DM8AI9U	Major	Additive CNS depression effects by the combination of Methadone and Loxapine.	Schizophrenia [6A20]	[81]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Methadone and Haloperidol.	Schizophrenia [6A20]	[25]
Perphenazine	DMA4MRX	Major	Increased risk of prolong QT interval by the combination of Methadone and Perphenazine.	Schizophrenia [6A20]	[25]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Methadone and Molindone.	Schizophrenia [6A20]	[27]
Chlorpromazine	DMBGZI3	Major	Increased risk of prolong QT interval by the combination of Methadone and Chlorpromazine.	Schizophrenia [6A20]	[25]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Methadone and Thiothixene.	Schizophrenia [6A20]	[81]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Methadone and Clozapine.	Schizophrenia [6A20]	[25]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Methadone and Trifluoperazine.	Schizophrenia [6A20]	[25]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Methadone and Risperidone.	Schizophrenia [6A20]	[25]
Olanzapine	DMPFN6Y	Major	Additive CNS depression effects by the combination of Methadone and Olanzapine.	Schizophrenia [6A20]	[81]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Methadone and Amisulpride.	Schizophrenia [6A20]	[31]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Methadone and Asenapine.	Schizophrenia [6A20]	[25]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Methadone and Pimozide.	Schizophrenia [6A20]	[28]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Methadone and Fentanyl.	Sensation disturbance [MB40]	[27]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Methadone and Vardenafil.	Sexual dysfunction [HA00-HA01]	[25]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Methadone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[32]
Telotristat ethyl	DMDIYFZ	Major	Increased metabolism of Methadone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[44]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Methadone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[32]
Armodafinil	DMGB035	Major	Increased metabolism of Methadone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[23]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Methadone and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[25]
Epirubicin	DMPDW6T	Major	Increased risk of prolong QT interval by the combination of Methadone and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[25]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Methadone and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[25]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Methadone and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[25]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Methadone and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[25]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Methadone and Pitolisant.	Somnolence [MG42]	[25]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Methadone and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[25]
Adenosine	DMM2NSK	Major	Increased risk of ventricular arrhythmias by the combination of Methadone and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[82]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Methadone due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[83]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Methadone caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[32]
Clopidogrel	DMOL54H	Moderate	Altered absorption of Methadone due to GI dynamics variation caused by Clopidogrel.	Thrombosis [DB61-GB90]	[71]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Methadone and Lenvatinib.	Thyroid cancer [2D10]	[25]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Methadone and Cabozantinib.	Thyroid cancer [2D10]	[25]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Methadone and Papaverine.	Tonus and reflex abnormality [MB47]	[84]
Tizanidine	DMR2IQ4	Major	Additive CNS depression effects by the combination of Methadone and Tizanidine.	Tonus and reflex abnormality [MB47]	[27]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Methadone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[80]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Methadone and Tacrolimus.	Transplant rejection [NE84]	[25]
Atropine	DMEN6X7	Moderate	Additive antimotility effects by the combination of Methadone and Atropine.	Unspecific substance harmful effect [NE6Z]	[52]
Elagolix	DMB2C0E	Major	Increased metabolism of Methadone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[23]
Astemizole	DM2HN6Q	Major	Increased risk of prolong QT interval by the combination of Methadone and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[25]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Methadone and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[48]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Methadone and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[85]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Methadone and Procainamide.	Ventricular tachyarrhythmia [BC71]	[25]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Methadone and Propafenone.	Ventricular tachyarrhythmia [BC71]	[25]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Methadone and Flecainide.	Ventricular tachyarrhythmia [BC71]	[25]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Methadone and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[25]
-----------


⏷ Show the Full List of 368 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Hydrazine yellow	E00409	164825	Colorant
Potassium phosphate monobasic	E00429	516951	Buffering agent
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
--------------------


⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Methadone 40 mg tablet	40 mg	Tablet for Oral Suspension	Oral
Methadone 5 mg tablet	5 mg	Oral Tablet	Oral
Methadone 10 mg tablet	10 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Methadone FDA Label
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. doi: 10.2165/00003088-200241140-00003.
4	BDDCS applied to over 900 drugs
5	Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug Alcohol Depend. 2014 Dec 1;145:185-93. doi: 10.1016/j.drugalcdep.2014.10.014. Epub 2014 Oct 24.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
9	In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology. 2007;80(4):304-11.
10	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
11	Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 Dec;50(6):551-9.
12	Bidirectional transfer of methadone across human placenta. Biochem Pharmacol. 2005 Jan 1;69(1):187-97.
13	Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
14	Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. doi: 10.1097/00008571-199610000-00004.
15	Methadone induces necrotic-like cell death in SH-SY5Y cells by an impairment of mitochondrial ATP synthesis. Biochim Biophys Acta. 2010 Nov;1802(11):1036-47. doi: 10.1016/j.bbadis.2010.07.024. Epub 2010 Aug 3.
16	Comparative effects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models. Toxicol In Vitro. 2010 Mar;24(2):630-7. doi: 10.1016/j.tiv.2009.10.005. Epub 2009 Oct 17.
17	Expression, purification, and characterization of mouse CYP2d22. Drug Metab Dispos. 2006 Jul;34(7):1167-74.
18	Psychoneuroendocrine effects of methadone maintenance. Psychoneuroendocrinology. 1989;14(5):371-91. doi: 10.1016/0306-4530(89)90007-3.
19	opioid receptor agonist-selective regulation of interleukin-4 in T lymphocytes. J Neuroimmunol. 2013 Oct 15;263(1-2):35-42. doi: 10.1016/j.jneuroim.2013.07.012. Epub 2013 Jul 25.
20	Adipocyte-derived hormones in heroin addicts: the influence of methadone maintenance treatment. Physiol Res. 2005;54(1):73-78. doi: 10.33549/physiolres.930568.
21	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
22	Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2. [PMID: 2891392]
23	Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
24	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
25	Canadian Pharmacists Association.
26	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
27	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
28	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29	Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
30	Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
31	Cerner Multum, Inc. "Australian Product Information.".
32	Bell J, Seres V, Bowron P, Lewis J, Batey R "The use of serum methadone levels in patients receiving methadone maintenance." Clin Pharmacol Ther 43 (1988): 623-9. [PMID: 3378383]
33	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
34	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
35	Liu S-J, Wang RI "Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome." Am J Psychiatry 141 (1984): 1287-8. [PMID: 6486271]
36	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
37	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
38	Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
39	Ehret GB, Desmeules JA, Broers B "Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology." Expert Opin Drug Saf 6 (2007): 289-303. [PMID: 17480178]
40	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
41	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
42	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
43	Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
44	Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM "Rifampin-induced methadone withdrawal." N Engl J Med 294 (1976): 1104-6. [PMID: 1256526]
45	Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
46	Abebe-Campino G, Offer D, Stahl B, Merlob P "Cardiac arrhythmia in a newborn infant associated with fluoxetine use during pregnancy." Ann Pharmacother 36 (2002): 533-4. [PMID: 11895072]
47	McCance-Katz EF, Mandell TW "Drug interactions of clinical importance with methadone and buprenorphine." Am J Addict 19 (2010): 2-3. [PMID: 20132116]
48	Gil M, Sala M, Anguera I, et al. "QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone." Am J Cardiol 92 (2003): 995-7. [PMID: 14556883]
49	Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
50	Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
51	Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
52	Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
53	Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM "The effect of fluconazole on the clinical pharmacokinetics of methadone." Clin Pharmacol Ther 63 (1998): 655-62. [PMID: 9663180]
54	De Bels D, Staroukine M, Devriendt J "Torsades de pointes due to methadone." Ann Intern Med 139 (2003): E156. [PMID: 12859181]
55	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
56	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
57	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
58	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
59	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
61	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
62	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
63	Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
64	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
65	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
66	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
67	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
68	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
69	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
70	Brown LS, Sawyer RC, Li R, Cobb MN, Colborn DC, Narang PK "Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users." Drug Alcohol Depend 43 (1996): 71-7. [PMID: 8957145]
71	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
72	Manara AR, Shelly MP, Quinn K, Park GR "The effect of metoclopramide on the absorption of oral controlled release morphine." Br J Clin Pharmacol 25 (1988): 518-21. [PMID: 3382595]
73	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
74	Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
75	Abernethy DR, Greenblatt DJ, Morse DS, Shader RI "Interaction of propoxyphene with diazepam, alprazolam and lorazepam." Br J Clin Pharmacol 19 (1985): 51-7. [PMID: 2858217]
76	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
77	Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
78	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
79	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
80	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
81	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
82	Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
83	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
84	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
85	Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.